Aditxt more than doubles after Appili takeover deadline extended

Appili Therapeutics

18/03/2025 15:07

** Shares of biotech firm Aditxt Inc ADTX.O rise 122% to $9.68

** ADTX's acquisition of Canada-based drug developer Appili Therapeutics APLI.TO has been given extended deadline of March 31, after APLI granted waiver

** APLI secured court approvals for transaction and its shareholders have voted in favor of deal

** However, deal remains subject to ADTX securing sufficient financing

** APLI to be delisted from Toronto Stock Exchange after acquisition, expected in Q1 2025

** More than 51.9 million ADTX shares traded, 73x their 25-day moving average

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))